Advances in Molecular Targeted Drugs for Hepatocellular Carcinoma
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2023.0605
- VernacularTitle:分子靶向药物治疗肝细胞癌的研究进展
- Author:
Yao-min WANG
1
;
Ya-ling LI
1
Author Information
1. Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
- Publication Type:Review
- Keywords:
hepatocellular carcinoma （HCC）;
molecular targeted drugs;
guidelines;
combination therapy;
sorafenib
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2023;44(6):915-924
- CountryChina
- Language:Chinese
-
Abstract:
Being the most common solid malignant tumor in the digestive system and the third leading cause of cancer-related death worldwide， hepatocellular carcinoma （HCC） is characterized by insidious onset， early recurrence/metastasis and poor prognosis. With the advantages of targeted precision， high specificity， minimal drug resistance， remarkable therapeutic efficacy and fewer side effects， molecular targeted drugs have become the hotspot and focus of tumor therapy research in recent years. As more is learned about the mechanism and clinical efficacy， some molecular targeted drugs have been recommended by HCC treatment guidelines. This paper reviewed the mechanism of HCC targeted therapy， molecular targeted drugs， relevant therapeutic protocols and outcomes so as to provide reference and evidence for subsequent research.
